PAVmed Inc. Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James

Reuters

06-03

<a href="https://laohu8.com/S/PAVM">PAVmed Inc.</a> Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James

PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, has announced a strategic partnership with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). This collaboration follows the successful completion of a pilot program utilizing the Veris Cancer Care Platform™. The partnership entails a long-term, multi-project agreement aimed at expanding the commercial use of the platform across various cancer care service lines, integrating it with electronic health records, and developing a large clinical registry. Additionally, a clinical trial for an implantable physiological monitor, pending FDA clearance, is set to launch next year. This initiative is part of the company's efforts to enhance cancer care through innovative digital health solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01921) on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540771958"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540771958\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540771958?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540771958","market":"us","top_or_hot":-1,"title":"PAVmed Inc. Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a> Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, has announced a strategic partnership with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). This collaboration follows the successful completion of a pilot program utilizing the Veris Cancer Care Platform™. The partnership entails a long-term, multi-project agreement aimed at expanding the commercial use of the platform across various cancer care service lines, integrating it with electronic health records, and developing a large clinical registry. Additionally, a clinical trial for an implantable physiological monitor, pending FDA clearance, is set to launch next year. This initiative is part of the company's efforts to enhance cancer care through innovative digital health solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01921) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PAVmed Inc. Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPAVmed Inc. Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-03 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a> Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, has announced a strategic partnership with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). This collaboration follows the successful completion of a pilot program utilizing the Veris Cancer Care Platform™. The partnership entails a long-term, multi-project agreement aimed at expanding the commercial use of the platform across various cancer care service lines, integrating it with electronic health records, and developing a large clinical registry. Additionally, a clinical trial for an implantable physiological monitor, pending FDA clearance, is set to launch next year. This initiative is part of the company's efforts to enhance cancer care through innovative digital health solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01921) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL6rkldz:1","article_id":"2540771958","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540771958","pubTimestamp":1748953881,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PAVmed Inc. Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James. PAVmed Inc. , a commercial-stage medical technology company, has announced a strategic partnership with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute . This collaboration follows the successful completion of a pilot program utilizing the Veris Cancer Care Platform. The partnership entails a long-term, multi-project agreement aimed at expanding the commercial use of the platform across various cancer care service lines, integrating it with electronic health records, and developing a large clinical registry. Additionally, a clinical trial for an implantable physiological monitor, pending FDA clearance, is set to launch next year. This initiative is part of the company's efforts to enhance cancer care through innovative digital health solutions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"PAVmed Inc.宣布与OSUCCC-James建立战略合作伙伴关系后启动Veris植入式生理监护仪的大型临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAVM":0.9},"content_text":"PAVmed Inc. Announces Launch of Large Clinical Trial for Veris Implantable Physiologic Monitor Following Strategic Partnership with OSUCCC - James\n    \n\n        PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, has announced a strategic partnership with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). This collaboration follows the successful completion of a pilot program utilizing the Veris Cancer Care Platform™. The partnership entails a long-term, multi-project agreement aimed at expanding the commercial use of the platform across various cancer care service lines, integrating it with electronic health records, and developing a large clinical registry. Additionally, a clinical trial for an implantable physiological monitor, pending FDA clearance, is set to launch next year. This initiative is part of the company's efforts to enhance cancer care through innovative digital health solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01921) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}